The National Academies Press

Currently Skimming:

Index
Pages 199-206

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 199... ... Index ^~pbe~ 18 ^cotoue' Ac-~Ids _o~ ~1 pleme~ 61 top-~- ~~- ~-61 He Amply 61 ^~^e, 17 Aged _~e Miens -~e, 10, he Genoa dea=;~=e deDd=^ ~ Ages cords Chic bygone, ~~~-1, ~e, 19, 21 B ~ 16 ;~~ agog ~m~o~^ 16 ~m~osuppresdo~ ~-~ T ~ 16 ~~ fir sac Is ad Dane 9, 11 I pa roam 11 prow =-~9 ~1 Ha 1 Cog B1 do tic ~~, re~end~o=, 1 1 tic Ha Bowl; 19 Ha _~ 10 , Marc ago Ha_ ~ ~ 19 Moue Ha modet -, 58-59, Dog SPIN 85 boa =~ 89 EDGE age 8 resay' ~o~ Ids Ha- of comply cot Ago r ~ ~ I E, ~all; G t~e, ~ Marc ~ ~=~c ~ ~89 Pate ~~ ~ =- Imp -91 recombs ~ ~~, ~~ Read the entire page →
From page 200... ... 200 risk assessment, 9~97 rodent immunoassay table, 86 test design, 92-94 Antibody defined, 9 hypersensitivity, 42 Antibody formation testing, 101-102 Antigen complement-mediated immune reaction, 29 defined, 9 Antimicrobial drug, 18 Antiparasitic drug, 18 Anxiety, multiple chemical sensi~civi~, 134 Aroclor, 75 Arrhythmia, air pollution, 131 Arsenic 70, 75 Arsine gas, 75 Arthritis autoimm unify, 145 multiple chemical sensitivity, 135 rheumatoid, 27, 54, 56 Asbestos, 70 Asthma, 14, 17, 34 36 air poDudo~ 1 autoimmun~, 145 defined, 11 detergent, 35 incidence, 35 mortality, 4~41 nickel, 35 nitrogen dioxide, 1 ozone, 1 palladium, 35 plating, 35 sulfite sensiduty, 38 tobacco, 130 toluene diisocyanate, 35 trimellitic anhydride, 35 Atama telan~ectasia, 65 Atopy, asthma, 35 Autoimmuni~, 2-3, 53-62 acetylation, 60 antinuclear antibody, 60-61 complement, 61 histopathologic e~iDation, 60-61 Awe complex, 61 tissue autoantibody, 60 animal model, 58-59 INDEX defined, 53 erythema multifo~llle, 57 genetic code, 55-56, 59 60 histocompatibilin,r complex, 59 immunoglobulin, 59 dence, 5~55 mech~mcm, 57-58 pharmaceutical worker, 3 recommendations, 61-62, 145 xenobiotic, `57 B cell age, 16 assay, 102 defined, 9 function, 2~26, 99 Bacteria, 24 Benzene, 11, 70, 75 immunosuppression, 72 Be~mdene, 70 Benzoic acid, 38 Benzophenone, 39 Beryllium disease, sarcoidos~ diagnosis, 14, 41 Biologic marker animal model, 83 98 auto~une disease, 53~2 class~cado~ ~ environlnental health, 127-139 epidemiology, 113-125 human marker, 99-111 ~mmune-mediated &ease, 3~52 immunosuppression' 6~82 recommendations, 141-148 validation, 19-20 Bone marrow, 31 arousal model, 89 Bronchoalveolar ravage, 76 hypersensitivity, 43 Bruton's disease, 65 Buchler test, 4S, 48 Belated hydro~y~mcole, 70 ButylEydro~y~nwol, 37 Bu~lLydro~toluene, 37 Cacosmia, air pollution, 131 Cadmium, 54 75 Read the entire page →
From page 201... ... INDEX Calcium, 70 Cannabionoid, 70 Captopril, 54 Carbon tetrachlonde, 75 Carrier protein 13 Cell-mediated immunity, defined, 9 Cellular ~mmU=ty animal model, 87-88 hypersensitivity, 42 testing, 102-104 Cellular interaction schema, 25 Cephalosporin, 58 Chediak-Higashi syndrome, 65 Chemical environments 127-139 Chemical sensitivity provocative challenge, 136 skin test, 137 syndrome, 128-L39 agent table, 129 classification, 128-130 recommendations, 138-139, 148 ChIorobenzene, 75 Chloroform, 75 Chromium, 75 ClEnical testing regimen, 4, 99 Cocame, 70 Cohort study, epidemiology, 113, 114 Common variable immunodefiaency, 65 Complement deficiency, 65 Complement-mediated ~jury, 27-29 Contact dermatitis, 38-39 Contact urtiG`ria, 39 40 Contraceptive, 18 Cosmetic, hypersensitivity, 10 Crobn's disease, 5~55 Cross-sectional study, epidemiology, 113114, 119 Cyclophosph~ide, 3, 58 immunosuppression, 17 Cyclosponn, 3, 11, 147 mn~unosllppression, 66 67 species comparison, immune response, 67 Depression air podunon, ~ multiple chemical sensitivity, 13~134 Dermal hypersensitivity, 3840 contact dermatitis, 38-39 201 contact urticaria, 3940 photocontact dermatitis, 39 Detergent, asthma, 35 Diabetes, 12, 27 Dichloroethane, 75 D~thloroethylene, 75 Diesel exhaust, 41 Diethylhe~yl pEthalate, 75 DiGeorge syndrome, 65 Dissociate, 11 Dime~y~ben7~nthracene, 147 Dioxin, 11 DiphenLydr~mine, 39 Diphenyl}~ydanto~ 70 Dodecylgallate, 37 Braise test, 45, 48 Drug, 18, 24 30 hypersensitivity, 10 immunoglobulin E hypersensitivity, 27 ~mmunosuppression, 70 Dye, 37 Dysphasia, Spinach toxic oil syndrome, 57 Education, recommendations, 147-148 Eject marker, overview, ~14 Electric shock, 24 Emotional dysfunction, 24 Endorphin, 17 Enkephalin, 17 Environmental control unit, inhalation challenge, 43, 139 Environmental exposure, recommendations, 148 Environmental health, controversial areas, 127-139 Environmental illness, 127,135 Environmental Protection Agency, 146 Epidemiology biologic markers, 4, 113125 case studies, 121-125 cohort study, 113, 114 cross-sectional study, 113114, 119 event status authentication, 117,119 hexametllylene dlisoc,~anate, 121-122 National Health and Nutritional EvaluatiOtl Survey, 121 predictive value, 1L5-117, 118 prospective study, 113, 120 Read the entire page →
From page 202... ... 45 46 technique, 11 45 anybody, 42 asthma, 14 beryllium lung disease, 14 biologic marker, 41~3 bronchoalveolar ravage, 43 cellular bumpy, 42 chemical detection schema, 48 clinical signs, 41 cosmetic, 10 dermal, 38� generally, 10 history, 41 immunoilobulin E, 2, 27, 42, 5~52 immunosuppres sion, It i n g u i she d, 34 ingestion, 37-38 Read the entire page →
From page 203... ... component aSthma' 26 structure, 2~26 xenobiotic, overview, 30-31 see also Immunoto~ncity Immunity assessment testing, 99-100 Immunogiobulin age, 16 autoimmuni~'r' 59 concentration testing, 100 101 isotype reference stance 20 smoldug, 18 munoiloblllin A deficiency, 65 Immunoglobulin E, 13 contact urticaria, 39 40 hapten, 52 hypersensitivity, 2, 27, 42, 50-52 Immunoglobulin G 13, U6 pregnancy, 15 Immunologic adjuvant, 40 TmmUDopotentiation, defined, 10 munosuppression, 14, 6~82 acquired immune deficiency syndrome, 63 age, 78-79 benzene, 72 consequences, ~K8 cyclophosph~de, 17 c~,rclosporin A, 66 67 defined, 10 environmental contaminant, 68-74 oundwater, 1, 7~75 hen mmunodefic~ency Virus, 63-64 203 hydrocarbon, 71-72 hypersensitivity, distinguished, 34 inhalation, 7~77 mechanistic study importance, 80 metabolism, 79-80 metal, 70, 73 myeloto~aty, 77-78 organ transplant, 64 65 recommendations, 81-82, 144 145 route of administration, 79 skin, 77 susceptibilibr, 78-80 syndrome chart, 65 tobacco, 79 Immunotomcin~r animal model, 8~98 auto~mmune disease, 53~2 complement-mediated ~jury, 27-29 environmental health, 127-139 epidemiology, 113 125 human marker, 99-111 hypersensitivity, 27 une-complex-mediated injury, 27-29 uDe-mediated disease marker, 33-52 immunosuppressive tome agents, 6~82 mechanism, 26-30 reco~nmendadons, 141-148 T cell reaction, 29-30 Immunoto~ncolo~ defined, 23 growtl1 of field, 23, 141 Infant-mother separation, 24 Ingestion, hypersensitivity, 37-38 Inh~ladon ~lveoiar macrophage, 76 bronchoalveolar-lavage, 76 �n~munosuppression, 7~77 Inhalation challenge en~o~ental control mat, 43 hypersensitivity, 43 Ineerleukin-1, adrenal cortical trophic hormone, 17 Iron, 19 Isobutyl nitrite, 7~75 Isoc3ranate, case study, 121-122 Kidney, 12 Read the entire page →
From page 204... ... 204 Langerh~ cell, ultraviolet, 19 Lead, 23, 70, 75 Lecithin, 37 Legionnaires' disease, 124 Leukemia, 17 tri~oroethylene, 11 well water, 123-124 Light immune function, 17 photoallergy, 39 solar uticaria, 19 ultraviolet, 19, 147 Lithium, 54, 70 Liver, 12 Lupus, pregnancy, AS Lymphopsrte antigen activation, 106107 assay, 103 104 defined, 9 function, 2~26 Lympholdne function, 2~26 lymphocyte activation secretion, 107 Lymphoma, 17 Mainounshment, 18-lg Marker, tennmology, 12 Mast cell, immunogloblllm E hypersensitivity, 27 Mechanistic study, animal model, 89-90 Mental dysfunction, 24 cY-Mercaptopropionylglycine, 54 Mercury, 54, 75 Metabolism, immunosuppression, 79-80 MetaL irnmunosuppressioD, 70, 73 Methyl mercury, 70 cx-MethyIdopa, 54 Methylene chloride, 75 Mouse-ear-swe~g test, 45, 48 Glucose response, 147 Mucous membrane, sick building syndrome, s Multiple chemical sensitivity, 127 anxiety, O4 Ids, us case definitions, 132-134 characterization Cullen, 132-134 INDEX Randolph, 132-133 defined, 133 depression, 13~134 formaldehyde-hmnan serum albumin, 137 mune-system dysfunction, 134 ~6 sick building syndrome, relationship, 132 terminology, 136 vascular dysfunction, ~135 Multiple personality disorder, immune function, 16 Myasthenia gram, 27, 54 Myeloma, 17 Myelotomcity, ~unosupression, 77-78 National Health and Nutritional Evaluation Survey, 491 National Institute for Occupational Safety "d Health, reference population, 120 National Institute of Environmental Health Sciences, 9, 11 National Research Councit 9, 11 National Toxicology Program, 10, 146 Natural kiBer cell, smoking, 18 Nervous-endocnne-~une axis, 2 Nervous system, immune system interaction, 1~17 Neurogenic factor, Theme function, 16 Neuropsychology, 21 NezeloPs syndrome, 65 Nickel, 38, 75 asthma, 35 Nitrogen dioxide, 40, 70 assume 1 autoimmun'~, 145 Nitro~=ine, 70 Noise, 24 Nonspecific immune enhancement, 40 41 Nonspecific immune, animal model, 88-89 Norepinephrine, 17 Occupational dermatitis, 11 Open epicutaneous test, 45, 48 Opioid, 70 Optimization test, 45, 48 Organ transplant, 11 ~mmunosuppression, 64 65 Organophosphate pesticide, 23 Read the entire page →
From page 205... ... L5 lupus, 15 Preservative, 37 Proc~nide, 15 Propyloc~l, 37 Prospective study, epidemiology, 113,120 Protozoa, 24 205 Provocation challenge, hypersensitivity, 42~3 Psychiatric disorder, ~ pollution, 130 Psychoneuroimmunology, 16 Psychoses, organ ophosphate pesticide, 130 Pulmonary hypersensitivity, 34 37 asthma, 34 36 lymph node, 35 pnemnonids, 36-37 rhinitis, 34 36 Pulmonary hypertension, Spanish tome oil syndrome, 57 Pulmonary immunocompetence, Cal model, 90-91 Pyrithio~e, 54 Radiation, 11, 24 Ragweed pollen, 11 Rapeseed oh 54 Raynaud's phenomenon, Spanish tome oil syndrome, 57 Reactive a~rways-dysfunction syndrome, 127, 130 Reference population Agency for Toxic Substances and Disease Re - my, 120 epidemiology, 120-121 National Institute for Occupational Safety and Health, 120 Respiratory tract, 34 37 Responsiveness decay, 13 Reticular dysgenesm, 65 Retrospective studies, epidemiology, 113, 114 Rhinitis, 34 36 Risk assessment, animal model, 9~97 Route of administration, immunosuppression, 79 Salipyl~ilide, 39 Sarcoidosm, beryllium disease, diagnosis' 41 Sclerosis, 54 SerotoDin, 17 Serum, antigen activation, 106-107 Serum protein, 27-29 Severe combined ~unodefiaengy &ease, 65 Siclc building syndrome, 127 epidemiology, 12~125 Read the entire page →
From page 206... ... 206 mucous membrane, 5 multiple chemical sensitivity, relationship, 132 Silica, 54 70 Silicone, 57 Sjogren's syndrome, Spanish tome oil syndrome, 57 Skin immunosu pp r e ss i on , 77 response, 147 testing, 41, 103 see also Dermal hypersensitivity Sodium benzoate, 37 Sodi~ gluten ate, 38 Sodi~ metabisulfite, 37 Sodium nitrite, 37 Solar urtica~ia see Lift Spanish toxic oil syndrome, 11, 57 Specificity biologic marker validation, 19-20 epidemiology, 115-117, 118 Split adjuvant technique, 45, 48 Staphylococcus enteroto~, 107 Stress, 21, 24, 130 glucocorticoid, 16 halopendol, 17 Study desk epidemiology, 119-120 Sulfanilamide, 39 Sulfite sensitivity, asthma, 38 Super dioxide, 40 Super antigen, 107 Susceptibility marker, overview, 1~19 Systemic lupus erythematosus, 54 T ceD age, 16 defined, 9 formaldehyde, 137 flmction, 2~26, 99 reaction, 29-30 Tartr~ne, 37, 54 Testing regimen, human immune system, 108-110 Tetrachlorodibenzo-p-dio~nn, 70 epidemiology, 122-123 Tetrachloroethylene, 75 Thymus gland, involution, 16 INDEX Thyroid disease, 54 Tobacco asthma, 130 epidemiology, 114 mmunoglobulin, 18 ~mmunosuppression, 79 natural killer cell, 18 To cop h er al, 37 Toluene, 70, 75 Toluene ddsocyanate, 11, 79 asthma, 35 Total Exposure Assessment Methodology, 128 Toxaphene, 23 Training, recommendations, 147-148 Trichloroacetic acid, perchloroethylene, 20 Trichloroethane, 75 Trichloroethanol, perchloroethylene, 20 Tnchloroethylene, 11, 57, 75 Trim ellitic anhydride, asthma, 35-36 Tnphenylmethane, 37 Tryptophan, 57 Ultraviolet see Light U.S. Environmental Protection Agency, 1, 9 Vaccine, ~unoglob''tin E hypersensitivity, 27 Variability of markers, L5-19, 26, 3S, 56, 7880, 82, iL5 Vascular dysfunction, multiple chemical sensitivity, ~335 Vinyl chlonde, 54 Virus, 24 Vitamin, 18, 19 Volatile organic compound, 128, 132, 137-138 Wed water, epidemiology, 123-124 Wiskott-Aldrich syndrome, 65 Xenobiotic defined, 10 immune system, overview, 30-31 Xylene, 75 Read the entire page →

From page 199...

... Index ^~pbe~ 18 ^cotoue' Ac-~Ids _o~ ~1 pleme~ 61 top-~- ~~- ~-61 He Amply 61 ^~^e, 17 Aged _~e Miens -~e, 10, he Genoa dea=;~=e deDd=^ ~ Ages cords Chic bygone, ~~~-1, ~e, 19, 21 B ~ 16 ;~~ agog ~m~o~^ 16 ~m~osuppresdo~ ~-~ T ~ 16 ~~ fir sac Is ad Dane 9, 11 I pa roam 11 prow =-~9 ~1 Ha 1 Cog B1 do tic ~~, re~end~o=, 1 1 tic Ha Bowl; 19 Ha _~ 10 , Marc ago Ha_ ~ ~ 19 Moue Ha modet -, 58-59, Dog SPIN 85 boa =~ 89 EDGE age 8 resay' ~o~ Ids Ha- of comply cot Ago r ~ ~ I E, ~all; G t~e, ~ Marc ~ ~=~c ~ ~89 Pate ~~ ~ =- Imp -91 recombs ~ ~~, ~~

Read the entire page →

From page 200...

... 200 risk assessment, 9~97 rodent immunoassay table, 86 test design, 92-94 Antibody defined, 9 hypersensitivity, 42 Antibody formation testing, 101-102 Antigen complement-mediated immune reaction, 29 defined, 9 Antimicrobial drug, 18 Antiparasitic drug, 18 Anxiety, multiple chemical sensi~civi~, 134 Aroclor, 75 Arrhythmia, air pollution, 131 Arsenic 70, 75 Arsine gas, 75 Arthritis autoimm unify, 145 multiple chemical sensitivity, 135 rheumatoid, 27, 54, 56 Asbestos, 70 Asthma, 14, 17, 34 36 air poDudo~ 1 autoimmun~, 145 defined, 11 detergent, 35 incidence, 35 mortality, 4~41 nickel, 35 nitrogen dioxide, 1 ozone, 1 palladium, 35 plating, 35 sulfite sensiduty, 38 tobacco, 130 toluene diisocyanate, 35 trimellitic anhydride, 35 Atama telan~ectasia, 65 Atopy, asthma, 35 Autoimmuni~, 2-3, 53-62 acetylation, 60 antinuclear antibody, 60-61 complement, 61 histopathologic e~iDation, 60-61 Awe complex, 61 tissue autoantibody, 60 animal model, 58-59 INDEX defined, 53 erythema multifo~llle, 57 genetic code, 55-56, 59 60 histocompatibilin,r complex, 59 immunoglobulin, 59 dence, 5~55 mech~mcm, 57-58 pharmaceutical worker, 3 recommendations, 61-62, 145 xenobiotic, `57 B cell age, 16 assay, 102 defined, 9 function, 2~26, 99 Bacteria, 24 Benzene, 11, 70, 75 immunosuppression, 72 Be~mdene, 70 Benzoic acid, 38 Benzophenone, 39 Beryllium disease, sarcoidos~ diagnosis, 14, 41 Biologic marker animal model, 83 98 auto~une disease, 53~2 class~cado~ ~ environlnental health, 127-139 epidemiology, 113-125 human marker, 99-111 ~mmune-mediated &ease, 3~52 immunosuppression' 6~82 recommendations, 141-148 validation, 19-20 Bone marrow, 31 arousal model, 89 Bronchoalveolar ravage, 76 hypersensitivity, 43 Bruton's disease, 65 Buchler test, 4S, 48 Belated hydro~y~mcole, 70 ButylEydro~y~nwol, 37 Bu~lLydro~toluene, 37 Cacosmia, air pollution, 131 Cadmium, 54 75

Read the entire page →

From page 201...

... INDEX Calcium, 70 Cannabionoid, 70 Captopril, 54 Carbon tetrachlonde, 75 Carrier protein 13 Cell-mediated immunity, defined, 9 Cellular ~mmU=ty animal model, 87-88 hypersensitivity, 42 testing, 102-104 Cellular interaction schema, 25 Cephalosporin, 58 Chediak-Higashi syndrome, 65 Chemical environments 127-139 Chemical sensitivity provocative challenge, 136 skin test, 137 syndrome, 128-L39 agent table, 129 classification, 128-130 recommendations, 138-139, 148 ChIorobenzene, 75 Chloroform, 75 Chromium, 75 ClEnical testing regimen, 4, 99 Cocame, 70 Cohort study, epidemiology, 113, 114 Common variable immunodefiaency, 65 Complement deficiency, 65 Complement-mediated ~jury, 27-29 Contact dermatitis, 38-39 Contact urtiG`ria, 39 40 Contraceptive, 18 Cosmetic, hypersensitivity, 10 Crobn's disease, 5~55 Cross-sectional study, epidemiology, 113114, 119 Cyclophosph~ide, 3, 58 immunosuppression, 17 Cyclosponn, 3, 11, 147 mn~unosllppression, 66 67 species comparison, immune response, 67 Depression air podunon, ~ multiple chemical sensitivity, 13~134 Dermal hypersensitivity, 3840 contact dermatitis, 38-39 201 contact urticaria, 3940 photocontact dermatitis, 39 Detergent, asthma, 35 Diabetes, 12, 27 Dichloroethane, 75 D~thloroethylene, 75 Diesel exhaust, 41 Diethylhe~yl pEthalate, 75 DiGeorge syndrome, 65 Dissociate, 11 Dime~y~ben7~nthracene, 147 Dioxin, 11 DiphenLydr~mine, 39 Diphenyl}~ydanto~ 70 Dodecylgallate, 37 Braise test, 45, 48 Drug, 18, 24 30 hypersensitivity, 10 immunoglobulin E hypersensitivity, 27 ~mmunosuppression, 70 Dye, 37 Dysphasia, Spinach toxic oil syndrome, 57 Education, recommendations, 147-148 Eject marker, overview, ~14 Electric shock, 24 Emotional dysfunction, 24 Endorphin, 17 Enkephalin, 17 Environmental control unit, inhalation challenge, 43, 139 Environmental exposure, recommendations, 148 Environmental health, controversial areas, 127-139 Environmental illness, 127,135 Environmental Protection Agency, 146 Epidemiology biologic markers, 4, 113125 case studies, 121-125 cohort study, 113, 114 cross-sectional study, 113114, 119 event status authentication, 117,119 hexametllylene dlisoc,~anate, 121-122 National Health and Nutritional EvaluatiOtl Survey, 121 predictive value, 1L5-117, 118 prospective study, 113, 120

Read the entire page →

From page 202...

... 45 46 technique, 11 45 anybody, 42 asthma, 14 beryllium lung disease, 14 biologic marker, 41~3 bronchoalveolar ravage, 43 cellular bumpy, 42 chemical detection schema, 48 clinical signs, 41 cosmetic, 10 dermal, 38� generally, 10 history, 41 immunoilobulin E, 2, 27, 42, 5~52 immunosuppres sion, It i n g u i she d, 34 ingestion, 37-38

Read the entire page →

From page 203...

... component aSthma' 26 structure, 2~26 xenobiotic, overview, 30-31 see also Immunoto~ncity Immunity assessment testing, 99-100 Immunogiobulin age, 16 autoimmuni~'r' 59 concentration testing, 100 101 isotype reference stance 20 smoldug, 18 munoiloblllin A deficiency, 65 Immunoglobulin E, 13 contact urticaria, 39 40 hapten, 52 hypersensitivity, 2, 27, 42, 50-52 Immunoglobulin G 13, U6 pregnancy, 15 Immunologic adjuvant, 40 TmmUDopotentiation, defined, 10 munosuppression, 14, 6~82 acquired immune deficiency syndrome, 63 age, 78-79 benzene, 72 consequences, ~K8 cyclophosph~de, 17 c~,rclosporin A, 66 67 defined, 10 environmental contaminant, 68-74 oundwater, 1, 7~75 hen mmunodefic~ency Virus, 63-64 203 hydrocarbon, 71-72 hypersensitivity, distinguished, 34 inhalation, 7~77 mechanistic study importance, 80 metabolism, 79-80 metal, 70, 73 myeloto~aty, 77-78 organ transplant, 64 65 recommendations, 81-82, 144 145 route of administration, 79 skin, 77 susceptibilibr, 78-80 syndrome chart, 65 tobacco, 79 Immunotomcin~r animal model, 8~98 auto~mmune disease, 53~2 complement-mediated ~jury, 27-29 environmental health, 127-139 epidemiology, 113 125 human marker, 99-111 hypersensitivity, 27 une-complex-mediated injury, 27-29 uDe-mediated disease marker, 33-52 immunosuppressive tome agents, 6~82 mechanism, 26-30 reco~nmendadons, 141-148 T cell reaction, 29-30 Immunoto~ncolo~ defined, 23 growtl1 of field, 23, 141 Infant-mother separation, 24 Ingestion, hypersensitivity, 37-38 Inh~ladon ~lveoiar macrophage, 76 bronchoalveolar-lavage, 76 �n~munosuppression, 7~77 Inhalation challenge en~o~ental control mat, 43 hypersensitivity, 43 Ineerleukin-1, adrenal cortical trophic hormone, 17 Iron, 19 Isobutyl nitrite, 7~75 Isoc3ranate, case study, 121-122 Kidney, 12

Read the entire page →

From page 204...

... 204 Langerh~ cell, ultraviolet, 19 Lead, 23, 70, 75 Lecithin, 37 Legionnaires' disease, 124 Leukemia, 17 tri~oroethylene, 11 well water, 123-124 Light immune function, 17 photoallergy, 39 solar uticaria, 19 ultraviolet, 19, 147 Lithium, 54, 70 Liver, 12 Lupus, pregnancy, AS Lymphopsrte antigen activation, 106107 assay, 103 104 defined, 9 function, 2~26 Lympholdne function, 2~26 lymphocyte activation secretion, 107 Lymphoma, 17 Mainounshment, 18-lg Marker, tennmology, 12 Mast cell, immunogloblllm E hypersensitivity, 27 Mechanistic study, animal model, 89-90 Mental dysfunction, 24 cY-Mercaptopropionylglycine, 54 Mercury, 54, 75 Metabolism, immunosuppression, 79-80 MetaL irnmunosuppressioD, 70, 73 Methyl mercury, 70 cx-MethyIdopa, 54 Methylene chloride, 75 Mouse-ear-swe~g test, 45, 48 Glucose response, 147 Mucous membrane, sick building syndrome, s Multiple chemical sensitivity, 127 anxiety, O4 Ids, us case definitions, 132-134 characterization Cullen, 132-134 INDEX Randolph, 132-133 defined, 133 depression, 13~134 formaldehyde-hmnan serum albumin, 137 mune-system dysfunction, 134 ~6 sick building syndrome, relationship, 132 terminology, 136 vascular dysfunction, ~135 Multiple personality disorder, immune function, 16 Myasthenia gram, 27, 54 Myeloma, 17 Myelotomcity, ~unosupression, 77-78 National Health and Nutritional Evaluation Survey, 491 National Institute for Occupational Safety "d Health, reference population, 120 National Institute of Environmental Health Sciences, 9, 11 National Research Councit 9, 11 National Toxicology Program, 10, 146 Natural kiBer cell, smoking, 18 Nervous-endocnne-~une axis, 2 Nervous system, immune system interaction, 1~17 Neurogenic factor, Theme function, 16 Neuropsychology, 21 NezeloPs syndrome, 65 Nickel, 38, 75 asthma, 35 Nitrogen dioxide, 40, 70 assume 1 autoimmun'~, 145 Nitro~=ine, 70 Noise, 24 Nonspecific immune enhancement, 40 41 Nonspecific immune, animal model, 88-89 Norepinephrine, 17 Occupational dermatitis, 11 Open epicutaneous test, 45, 48 Opioid, 70 Optimization test, 45, 48 Organ transplant, 11 ~mmunosuppression, 64 65 Organophosphate pesticide, 23

Read the entire page →

From page 205...

... L5 lupus, 15 Preservative, 37 Proc~nide, 15 Propyloc~l, 37 Prospective study, epidemiology, 113,120 Protozoa, 24 205 Provocation challenge, hypersensitivity, 42~3 Psychiatric disorder, ~ pollution, 130 Psychoneuroimmunology, 16 Psychoses, organ ophosphate pesticide, 130 Pulmonary hypersensitivity, 34 37 asthma, 34 36 lymph node, 35 pnemnonids, 36-37 rhinitis, 34 36 Pulmonary hypertension, Spanish tome oil syndrome, 57 Pulmonary immunocompetence, Cal model, 90-91 Pyrithio~e, 54 Radiation, 11, 24 Ragweed pollen, 11 Rapeseed oh 54 Raynaud's phenomenon, Spanish tome oil syndrome, 57 Reactive a~rways-dysfunction syndrome, 127, 130 Reference population Agency for Toxic Substances and Disease Re - my, 120 epidemiology, 120-121 National Institute for Occupational Safety and Health, 120 Respiratory tract, 34 37 Responsiveness decay, 13 Reticular dysgenesm, 65 Retrospective studies, epidemiology, 113, 114 Rhinitis, 34 36 Risk assessment, animal model, 9~97 Route of administration, immunosuppression, 79 Salipyl~ilide, 39 Sarcoidosm, beryllium disease, diagnosis' 41 Sclerosis, 54 SerotoDin, 17 Serum, antigen activation, 106-107 Serum protein, 27-29 Severe combined ~unodefiaengy &ease, 65 Siclc building syndrome, 127 epidemiology, 12~125

Read the entire page →

From page 206...

... 206 mucous membrane, 5 multiple chemical sensitivity, relationship, 132 Silica, 54 70 Silicone, 57 Sjogren's syndrome, Spanish tome oil syndrome, 57 Skin immunosu pp r e ss i on , 77 response, 147 testing, 41, 103 see also Dermal hypersensitivity Sodium benzoate, 37 Sodi~ gluten ate, 38 Sodi~ metabisulfite, 37 Sodium nitrite, 37 Solar urtica~ia see Lift Spanish toxic oil syndrome, 11, 57 Specificity biologic marker validation, 19-20 epidemiology, 115-117, 118 Split adjuvant technique, 45, 48 Staphylococcus enteroto~, 107 Stress, 21, 24, 130 glucocorticoid, 16 halopendol, 17 Study desk epidemiology, 119-120 Sulfanilamide, 39 Sulfite sensitivity, asthma, 38 Super dioxide, 40 Super antigen, 107 Susceptibility marker, overview, 1~19 Systemic lupus erythematosus, 54 T ceD age, 16 defined, 9 formaldehyde, 137 flmction, 2~26, 99 reaction, 29-30 Tartr~ne, 37, 54 Testing regimen, human immune system, 108-110 Tetrachlorodibenzo-p-dio~nn, 70 epidemiology, 122-123 Tetrachloroethylene, 75 Thymus gland, involution, 16 INDEX Thyroid disease, 54 Tobacco asthma, 130 epidemiology, 114 mmunoglobulin, 18 ~mmunosuppression, 79 natural killer cell, 18 To cop h er al, 37 Toluene, 70, 75 Toluene ddsocyanate, 11, 79 asthma, 35 Total Exposure Assessment Methodology, 128 Toxaphene, 23 Training, recommendations, 147-148 Trichloroacetic acid, perchloroethylene, 20 Trichloroethane, 75 Trichloroethanol, perchloroethylene, 20 Tnchloroethylene, 11, 57, 75 Trim ellitic anhydride, asthma, 35-36 Tnphenylmethane, 37 Tryptophan, 57 Ultraviolet see Light U.S. Environmental Protection Agency, 1, 9 Vaccine, ~unoglob''tin E hypersensitivity, 27 Variability of markers, L5-19, 26, 3S, 56, 7880, 82, iL5 Vascular dysfunction, multiple chemical sensitivity, ~335 Vinyl chlonde, 54 Virus, 24 Vitamin, 18, 19 Volatile organic compound, 128, 132, 137-138 Wed water, epidemiology, 123-124 Wiskott-Aldrich syndrome, 65 Xenobiotic defined, 10 immune system, overview, 30-31 Xylene, 75

Read the entire page →

← Previous Chapter Skim

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

Index Pages 199-206

Index
Pages 199-206